Utah Medical Products (NASDAQ:UTMD) Stock Price Passes Above 200 Day Moving Average – Time to Sell?

Utah Medical Products, Inc. (NASDAQ:UTMD)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $60.86 and traded as high as $71.81. Utah Medical Products shares last traded at $70.65, with a volume of 21,879 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Utah Medical Products from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Utah Medical Products presently has an average rating of “Hold”.

Utah Medical Products Price Performance

The stock has a market capitalization of $224.67 million, a price-to-earnings ratio of 20.30 and a beta of 0.35. The stock has a 50-day moving average of $64.99 and a 200 day moving average of $60.85.

Utah Medical Products (NASDAQ:UTMD) last released its earnings results on Thursday, January 29th. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter. Utah Medical Products had a net margin of 29.30% and a return on equity of 9.56%. The company had revenue of $9.05 million for the quarter.

Utah Medical Products Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 3rd. Shareholders of record on Tuesday, March 17th were given a dividend of $0.31 per share. The ex-dividend date was Tuesday, March 17th. This represents a $1.24 annualized dividend and a dividend yield of 1.8%. Utah Medical Products’s payout ratio is presently 35.63%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in UTMD. Comerica Bank grew its stake in shares of Utah Medical Products by 435.6% during the third quarter. Comerica Bank now owns 541 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 440 shares during the period. BNP Paribas Financial Markets boosted its holdings in Utah Medical Products by 89.6% during the third quarter. BNP Paribas Financial Markets now owns 1,060 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 501 shares during the last quarter. CWM LLC grew its position in shares of Utah Medical Products by 60.4% during the 3rd quarter. CWM LLC now owns 1,330 shares of the medical instruments supplier’s stock worth $84,000 after buying an additional 501 shares during the period. Cornerstone Planning Group LLC grew its position in shares of Utah Medical Products by 3,272.5% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,349 shares of the medical instruments supplier’s stock worth $85,000 after buying an additional 1,309 shares during the period. Finally, State of Wyoming bought a new stake in shares of Utah Medical Products in the 2nd quarter valued at about $132,000. 69.60% of the stock is currently owned by institutional investors.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single?use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non?invasive monitoring products used in acute and long?term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end?tidal carbon dioxide (CO?).